Abstract Immunomodulatory drugs (IMiDs) are associated with an increased risk of arterial thromboembolism (ATE) in multiple myeloma (MM), but determinants and mechanisms remain poorly defined. We evaluated incidence, timing, and clinical risk factors in 4287 patients with newly diagnosed MM from the Myeloma-XI-trial; all received IMiD-based induction and 1412 were randomised to Lenalidomide (Len) maintenance.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Elsa
Contact Elsa, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack